ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning:...

|By:, SA News Editor

ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning: Navidea (NAVB +3.7%), BioMarin (BMRN +4.5%), Corcept Therapeutics (CORT +4%), Medivation (MDVN +5.2%), Amicus Theraputics (FOLD +2%), Raptor Pharmaceuticals (RPTP +0.2%), Synageva BioPharma (GEVA +3.2%), Aegerion (GEVA +3.7%).